

# Shang Su

Post-doctoral Fellow, Xiaohong Li lab  
University of Toledo, Department of Cancer Biology  
Toledo, OH 43614, US  
Work: 1-419-383-4446  
Email: shang.su@utoledo.edu

---

## Education

Tsinghua University, Beijing

Sep 2011-Oct 2019

- Ph. D. in biology

Tsinghua University, Beijing

Sep 2007-Jul 2011

- B. Sc. in biology

## Research Experiences

University of Toledo Medical Center

Jul 2020- present

Van Andel Institute

May 2019- Jun 2020

Supervisor: Dr. Xiaohong Li

*Prostate cancer bone metastasis, drug resistance and Tumor dormancy*

- Deciphering how bone microenvironment (mainly on osteoblast) is involved in metastasis and enzalutamide resistance of prostate cancer.
- Developing novel system to detect and monitoring tumor cell dormancy and re-proliferation.

Tsinghua University

Sep 2010- Jul 2018

Supervisor: Dr. Wei Wu & Dr. Yu Rao

*Targeted degradation of cancer therapeutic targets*

- Developed small-molecule degrader of therapeutic proteins by PROTAC to overcome drug resistance.
- Integrated biochemical/cellular/fluorescence microscopic techniques to characterize the potent PROTACs.

Supervisor: Dr. Wei Wu

*Cell cycle regulation in cancer cells*

- Discovered S/G2-phase enrichment of  $\beta$ -catenin/TCF transcriptional complex in colorectal cancer cells.
- Deciphered the upstream and downstream events of  $\beta$ -catenin/TCF enrichment to learn more on cell cycle.

## Publications

4 peer-reviewed research articles, 1 invited review and 1 preprint. H-index=4. Total citations >60 since 2014.

1. **Su S<sup>#</sup>**, Cao J<sup>#</sup>, Meng X<sup>#</sup>, et al.. Enzalutamide-induced PTH1R-mediated TGFBR2 decrease in osteoblasts contributes to resistance in prostate cancer bone metastases. **BioRxiv**, 2020. DOI: 10.1101/829044. In Revision (#, co-first author)

2. **Su S<sup>#</sup>**, Yang Z<sup>#</sup>, Gao H, et al.. Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera. **Journal of Medicinal Chemistry**, 2019, 62 (16), 7575-7582. (#, co-first author)

3. An Z, Lv W, **Su S**, et. al.. Developing potent PROTACs tools for selective degradation of HDAC6 protein. **Protein & Cell**, 2019, 10(8): 606-609.

4. Zhao Q, Lan T, **Su S**, Rao Y. Induction of Apoptosis in MDA-MB-231 Breast Cancer Cells by a PARP1-Targeting PROTAC Small Molecule. **Chemical Communications**, 2019, 55 (3), 369-372.

5. Ding Y<sup>#</sup>, **Su S<sup>#</sup>**, Tang W, et. al.. Enrichment of the  $\beta$ -catenin–TCF complex at the S and G2 phases ensures cell survival and cell cycle progression. **Journal of Cell Science**, 2014, 127: 4833-4845. (#, co-first author)

6. **Su S**, Wu W. Regulation of target gene transcription by Wnt/ $\beta$ -catenin signaling. **SCIENTIA SINICA Vitae**, 2014, 44: 1029–1042. (Invited review in Chinese)

## Invited talks and presentations

**2019 Sep** Enzalutamide down-regulation of TGFBR2 in osteoblasts contributes to resistance in prostate cancer bone metastasis. Oral Presentation at Cold Spring Harbor Meeting “Biology of Cancer: microenvironment & metastasis”.

## **Teaching Experiences**

**2019 Winter, Group Leader** for High School Journal Club in Van Andel Education Institute.

**2019 Winter & 2020 Spring, Instructor** for Internal Seminar Course in Graduate School of Van Andel Institute.

## **Awards and Honors**

- Excellent PhD student list in School of Life Sciences, Tsinghua University 2016
- Tsinghua Scholarship for Graduate Student, “WU Zhengyi 3-generation” Memorial Award 2014
- Level I Excellent Graduates of Tsinghua University (TOP 2% among 3000 graduates) 2011